Abstract 1958P
Background
HN-STS is a challenging disease due to its diverse clinical presentation. In an attempt to refine the prognostication of these pts, the AJCC in its 8th edition proposed a new dedicated T staging group based on cutoffs of 2 and 4 cm for classifying T1, T2 and T3, and surrounding tissue invasion as T4, as opposed to the dichotomic T1-T2 5cm cutoff adopted by the 7th AJCC.
Methods
This is a retrospective study of pts diagnosed with nonmetastatic HN-STS treated with curative intent in a single tertiary hospital, approved by the institutional ethical review committee. The aim was to compare the 8th AJCC T staging to the previous classification as a prognostic tool for HN-STS, added to other variables such as age, histological subtype, grade and regional lymph node metastasis (LNM). AJCC 7th and 8th have been compared regarding T staging with Cohen’s kappa coefficient (KC) using inter-rater agreement analysis. The Kaplan-Meier estimator was used to calculate median survival time and differences in time-to-event outcomes were assessed using the log-rank test. Cox proportional hazard model was used to assess the effect of features in overall survival (OS).
Results
From 1997 to 2000, 135 pts were identified in institutional archives. Sarcoma NOS (N=50) and Leiomyosarcoma (N=17) were the most common histologic subtypes, as well as high-grade tumors (N=85). KC of inter-rater agreement was 0.46, statistically significant (p=0.03), indicating poor agreement between both T staging systems. Regarding OS, AJCC 7th (T1 and T2) and 8th (T1, T2, T3 and T4) T size stratification was not statistically different (P=0.42 and P=0.27, respectively). High-grade (71.4% vs 93.6%, P=0.005) and regional LNM (31.3% vs 81.4%, P=0.008) had worse 5-year OS in Cox multivariate analysis. Pts with tumor size>4cm or local invasion, high grade and LNM had 2.30, 7.11 and 4.37-fold increased risk of death respectively.
Conclusions
In our series, neither 7th nor 8th AJCC T size classifications adequately stratified prognostic groups or correlated survival for HN-STS pts. The 8th AJCC T4, the high-grade tumors and regional LNM demonstrated significant worse prognostic impact in pts harboring HN-STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15